We value your privacy
We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.
Clinical Trials
56
2 active
Approvals
0
Total approvals
Agencies
Regulatory bodies
Founded
1964
Completed
26
46.4%
Not yet recruiting
2
3.6%
Recruiting
8
14.3%
Terminated
6
10.7%
Unknown
13
23.2%
Withdrawn
1
1.8%
No approval data available
- Phase 3 WAYPOINT trial demonstrates tezepelumab significantly reduced nasal polyp severity and improved nasal congestion scores in patients with severe chronic rhinosinusitis with nasal polyps. - The study showed a dramatic 92% reduction in the need for nasal polyp surgery or systemic corticosteroid treatment compared to placebo over 52 weeks. - Patients receiving tezepelumab experienced significant improvements in multiple symptoms, including loss of smell and sino-nasal outcomes, with similar adverse event rates to placebo.
